MEPI-AVC - Evaluation of the efficacy and safety of mepivacaine on the neurological sequelae of cerabral infarction

Prior treatment

• Hypersensitivity to amide-bonded local anesthetics. Atrioventricular conduction disorders requiring permanent electro-systolic training not yet performed. Epilepsy not controlled by treatment. Porphyritic subjects. Patients with a motor deficit (but no aphasia or scotomas) in whom there is spasticity leading to a major reduction in joint amplitude in passive motion Minor patients, under curatorship or guardianship, under legal protection, deprived of liberty, pregnant or breastfeeding women Pathologies involving the vital prognosis or compromising follow-up during the study period Patient undergoing local amine anesthesia in the 7 days preceding V1. Patients currently treated with no anti-arrhythmics such as tocainide, aprindine and mexiletine Patients with a contraindication to MRI (ferro-magnetic surgical clips, eye implants, metallic foreign body intraocular or in the nervous system, implants or metallic objects likely to contain the radiofrequency field, cochlear implants, cerebral or cardiac pacemaker , implantable cardiac defibrillators) Patients participating in research involving the therapeutic human person who may modify functional recovery (whether by medication or by medical device) or subject to an exclusion period for another research

• Ischemic stroke more than 30 days old Age between 18 and 85 years old At least one deficit among: motor deficit: score < 56 on the Fugl-Meyer scale aphasia: score ≥4 on the Aphasia Rapid Test, presence of a clinically observable visual scotoma Having given their written consent Be affiliated with a social security scheme, Universal Medical Coverage (CMU) or any equivalent scheme